Many of us believe that prostate cancer is one specific disease, however this is not true. In fact we now know that there are at least twenty-three different types off prostate cancer. The most common types of prostate cancer, or ninety-five percent of them are referred to as adenocarcinomas. One of the least common types [...]
Sequencing of the various new advanced prostate cancer treatments remains a hot topic in our community. What treatment should come first and will the combination of various treatments be even more effective? These types of questions are constantly buzzing around us and they will continue to as long as we develop new treatments. The only [...]
The Journal of Clinical Oncology, published an article by Niraula et al. that searched the general literature published through August 2012. They searched MEDLINE, EMBASE, the Cochrane Library, as well as most major conference proceedings. Their criteria for inclusion included randomized, controlled trials of intermittent hormone therapy (IADT) as compared to continuous hormone therapy (CADT) [...]
GTx Inc. had a poster honored as one of the best posters at the 28th Annual European Association of Urology Congress held in Milan Italy March 15 2013. The poster presentation which had the very long title of “GTx-758 an ERa Agonist Reduces Serum Free Testosterone Lower than can be Achieved by Leuprolide with a [...]
My friend and colleague, Richard Wassersug published an article on April 4, 2013 on the on-line service, Uro-Today.com, about the lack of reliability on internet sites when they discuss hormone therapy. Dr. Wassersug is a Professor in the Department of Anatomy and Neurobiology at Dalhousie University, Canada. His research interests include the Psychosocial impact of [...]